Pasotuxizumab

Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE) . Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) [1][2].

Product Specifications

CAS Number

[1442657-12-6]

Product Name Alternative

BAY 2010112; AMG 212; MT112

UNSPSC

12352203

Target

CD3

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pasotuxizumab.html

Purity

98.111

Solubility

10 mM in DMSO

Smiles

[Pasotuxizumab]

Molecular Weight

(53.55 kDa)

References & Citations

[1]Horst-Dieter Hummel, et al. Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC) . Journal of Clinical Oncology 2019 37:15_suppl, 5034-5034. |[2]Friedrich M, et al. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther. 2012 Dec;11 (12) :2664-73.